Lipitor Lawsuit News: Discovery Moves Ahead in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports
New York, New York (PRWEB) January 21, 2015 -- Hundreds of Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) that allege use of the statin medication caused some patients to develop new-onset Type 2 diabetes continue to move forward in the federal multidistrict litigation underway in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to court documents, the parties submitted a Joint Status Report to the Court on January 15th, in advance of the litigation’s upcoming Status Conference. Among other things, the report notes that discovery in the litigation is ongoing, with plaintiffs completing deposition of a number of current and former Pfizer, Inc. employees. Additional witnesses are scheduled to be deposed later this month. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is currently representing clients in Lipitor lawsuits who allegedly developed diabetes due to their use of the statin medication. We are pleased to see that discovery is well underway in the federal proceeding, and look forward the January 22nd conference,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Litigation
Court documents indicate that more than 1,600 Lipitor diabetes claims are currently pending in the U.S. District Court, District of South Carolina. The litigation has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) announced that the labels for Lipitor and other statins would be updated to include new information about their potential association with Type 2 diabetes. The label change was prompted by the publication of a study in JAMA: Internal Medicine the previous month which suggested that post-menopausal women treated with statins faced an increased risk of developing new-onset Type 2 diabetes. *
According to court records, all of the Lipitor lawsuits now pending in the federal proceeding accuse Pfizer Inc. of endeavoring to protect sales of the drug by concealing its alleged association with diabetes. According to court documents, plaintiffs further allege that they would not have used Lipitor, or would have been more closely monitored for diabetes, had Pfizer’s warnings been adequate. The lawsuits also assert that the label modifications made by Pfizer in the wake of the FDA’s 2012 warning still do not sufficiently inform patients about the potential association between Lipitor and diabetes.
Lipitor patients who allegedly developed Type 2 diabetes due to the medication may be entitled to compensation from Pfizer. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.lipitorlawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Lipitor Lawsuit Diabetes Center, http://www.lipitorlawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article